Skip to main content
logo
Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
13.86
-0.18 (-1.28%)
At close: Jul 10, 2026, 4:00 PM EDT
13.72
-0.14 (-1.01%)
After-hours: Jul 10, 2026, 4:10 PM EDT

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Jan '20 Dec '18 Dec '17 Dec '16
Ruconest®
317.92M252.24M227.13M205.62M-
Ruconest® Growth
26.04%11.05%10.46%--
Joenja®
58.21M44.96M18.18M--
Joenja® Growth
29.47%147.28%---
Recombinant Human C1 Esterase Inhibitor Business
----198.87M
Recombinant Human C1 Esterase Inhibitor Business Growth
-----6.27%
Total
376.13M297.20M245.32M205.62M198.87M
Total Growth
26.56%21.15%19.30%3.39%-6.27%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Jan '20 Dec '18 Dec '17 Dec '16
United States (US)
361.75M287.15M239.11M200.08M193.42M
United States (US) Growth
25.98%20.09%19.50%3.44%-4.57%
Europe and The Rest of The World
14.39M10.05M6.21M5.54M5.45M
Europe and The Rest of The World Growth
43.15%61.88%12.08%1.61%-
Total
376.13M297.20M245.32M205.62M198.87M
Total Growth
26.56%21.15%19.30%3.39%-6.27%